Azercabtagene zapreleucel is under clinical development by Precision Biosciences and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Azercabtagene zapreleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Azercabtagene zapreleucel overview

Azercabtagene zapreleucel (PBCAR-0191) is under development for the treatment of graft vs host disease, relapsed or refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma including diffuse large B cell lymphoma, follicular lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma and high grade B cell lymphoma. It is administered through intravenous route. The therapeutic candidate constitutes of allogenic anti-CD19 chimeric antigen receptor (CAR) T cells. It is developed based on the ARCUS technology platform. It is a genome editing platform derived from a natural genome editing enzyme called homing endonuclease which incorporates Adeno-associated virus (AAV) vector. It acts by targeting cells expressing the CD19 protein.

Precision Biosciences overview

Precision Biosciences is a biotechnology company, that develops and commercializes gene therapy and cancer immunotherapy. The company focuses its ARCUS technology, a proprietary genome editing platform, which combines specificity and efficacy, on the development of food, fuel, and feed-based products. Precision BioSciences ARCUS technology helps improve genes related to crop quality, yield, and performance traits, and strives to advance food products. The company also applies its ARCUS technology for the development of cell-based immunotherapies to cure genetic diseases. Precision BioSciences genome editing platform is derived from a natural genome editing enzyme, homing endonuclease. The company partners with various pharmaceutical and biotech companies to develop novel therapies for the treatment of cancer. Precision BioSciences is headquartered in Durham, North Carolina, the US.

For a complete picture of Azercabtagene zapreleucel’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.